MicroRNA‑877 inhibits cell proliferation and invasion in non‑small cell lung cancer by directly targeting IGF‑1R Retraction in /10.3892/etm.2022.11588

Zhou,Guohua; Xie,Jinglian; Gao,Zikun; Yao,Weishen

doi:10.3892/etm.2019.7676

MicroRNA‑877 inhibits cell proliferation and invasion in non‑small cell lung cancer by directly targeting IGF‑1R

Retraction in: /10.3892/etm.2022.11588

Authors:
- Guohua Zhou
- Jinglian Xie
- Zikun Gao
- Weishen Yao
View Affiliations

Affiliations: Department of Thoracic Surgery, Affiliated Nanhai Hospital, Southern Medical University (People's Hospital of Nanhai District), Foshan, Guangdong 528000, P.R. China
Published online on: June 14, 2019 https://doi.org/10.3892/etm.2019.7676
Pages: 1449-1457

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) are frequently differentially expressed in non‑small cell lung cancer (NSCLC), and differential miRNAs expression may be closely associated with NSCLC genesis and development. Therefore, an in‑depth investigation of the cancer‑associated miRNAs that are crucial for NSCLC pathogenesis may provide effective therapeutic targets for patients with this aggressive malignant tumor type. The expression levels and roles of miR‑877 have been well studied in hepatocellular carcinoma and renal cell carcinoma. However, the expression pattern and functions of miR‑877 in NSCLC as well as associated underlying mechanisms, to the best of our knowledge, have not yet been investigated. The present study revealed that miR‑877 expression was downregulated in NSCLC tissues and cell lines. Low miR‑877 expression was significantly associated with TNM stage and distant metastasis in patients with NSCLC. Functional experiments demonstrated that recovery of miR‑877 expression restricted the proliferation and invasion of NSCLC cells. In addition, bioinformatics analysis predicted insulin‑like growth factor 1 receptor (IGF‑1R) as a potential target of miR‑877. Luciferase reporter assays, reverse transcription‑quantitative PCR and western blot analysis further validated that IGF‑1R was a direct target of miR‑877 in NSCLC. Furthermore, IGF‑1R expression was markedly upregulated in NSCLC tissues, and exhibited an inverse correlation with miR‑877 expression. Additionally, IGF‑1R overexpression reversed the inhibitory effects in NSCLC cells caused by miR‑877 upregulation. These findings demonstrated that miR‑877 attenuated NSCLC cell proliferation and invasion, at least partly, by downregulating IGF‑1R expression, thereby providing an new candidate biomarker for the diagnosis and therapy of patients with NSCLC.

View Figures

View References

1	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zheng M: Classification and pathology of lung cancer. Surg Oncol Clin N Am. 25:447–468. 2016. View Article : Google Scholar : PubMed/NCBI
4	Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801. 2010. View Article : Google Scholar : PubMed/NCBI
5	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions, : The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
6	Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003. View Article : Google Scholar : PubMed/NCBI
7	Link A and Kupcinskas J: MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives. World J Gastroenterol. 24:3313–3329. 2018. View Article : Google Scholar : PubMed/NCBI
8	Ramassone A, Pagotto S, Veronese A and Visone R: Epigenetics and MicroRNAs in Cancer. Int J Mol Sci. 19(pii): E4592018. View Article : Google Scholar : PubMed/NCBI
9	Pratap P, Raza ST, Abbas S and Mahdi F: MicroRNA-associated carcinogenesis in lung carcinoma. J Cancer Res Ther. 14:249–254. 2018.PubMed/NCBI
10	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
11	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
12	Altana V, Geretto M and Pulliero A: MicroRNAs and physical activity. Microrna. 4:74–85. 2015. View Article : Google Scholar : PubMed/NCBI
13	Lu J, Zhan Y, Feng J, Luo J and Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI
14	Shishodia G, Verma G, Das BC and Bharti AC: miRNA as viral transcription tuners in HPV-mediated cervical carcinogenesis. Front Biosci (Schol Ed). 10:21–47. 2018. View Article : Google Scholar : PubMed/NCBI
15	To KK, Tong CW, Wu M and Cho WC: MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. World J Gastroenterol. 24:2949–2973. 2018. View Article : Google Scholar : PubMed/NCBI
16	Sharma N and Baruah MM: The microRNA signatures: Aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol. 21:126–144. 2019. View Article : Google Scholar : PubMed/NCBI
17	Piasecka D, Braun M, Kordek R, Sadej R and Romanska H: MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018. View Article : Google Scholar : PubMed/NCBI
18	Fadejeva I, Olschewski H and Hrzenjak A: MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI
19	Zhou Q, Huang SX, Zhang F, Li SJ, Liu C, Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 50:e 123942017. View Article : Google Scholar
20	Yan TH, Qiu C, Sun J and Li WH: MiR-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 22:3038–3046. 2018.PubMed/NCBI
21	Huang X, Qin J and Lu S: Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1. Int J Clin Exp Pathol. 8:1515–1524. 2015.PubMed/NCBI
22	Shi Q, Xu X, Liu Q, Luo F, Shi J and He X: MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma. Oncol Lett. 11:1474–1480. 2016. View Article : Google Scholar : PubMed/NCBI
23	Woodard GA, Jones KD and Jablons DM: Lung cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo R, Tofanetti FR, Mameli MG, et al: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 20:842–849. 2009. View Article : Google Scholar : PubMed/NCBI
26	Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, et al: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol. 21:562–567. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T and Mishima M: Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer. Clin Lung Cancer. 13:385–390. 2012. View Article : Google Scholar : PubMed/NCBI
28	Tsuta K, Mimae T, Nitta H, Yoshida A, Maeshima AM, Asamura H, Grogan TM, Furuta K and Tsuda H: Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lung carcinomas. Hum Pathol. 44:975–982. 2013. View Article : Google Scholar : PubMed/NCBI
29	Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F and O'Byrne KJ: High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clin Lung Cancer. 15:58–66. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zhao S, Qiu Z, He J, Li L and Li W: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: A meta-analysis. Int J Clin Exp Pathol. 7:6694–6704. 2014.PubMed/NCBI
31	Nakagawa M, Uramoto H, Oka S, Chikaishi Y, Iwanami T, Shimokawa H, So T, Hanagiri T and Tanaka F: Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer. 13:136–142. 2012. View Article : Google Scholar : PubMed/NCBI
32	Vilmar A, Santoni-Rugiu E, Cillas JG, Huarriz M and Sørensen JB: Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer. Anticancer Res. 34:2991–2996. 2014.PubMed/NCBI
33	Liu F, Liu Y, Liu X, Mao K, Zhong D, Marcus AI, Khuri FR, Sun SY, He Y and Zhou W: Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer. 123:36–43. 2018. View Article : Google Scholar : PubMed/NCBI
34	Yeo CD, Kim YA, Lee HY, Kim JW, Lee SH, Kim SJ, Kwon SS, Kim YH and Kim SC: Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells. Exp Lung Res. 43:29–37. 2017. View Article : Google Scholar : PubMed/NCBI
35	Zhao FY, Han J, Chen XW, Wang J, Wang XD, Sun JG and Chen ZT: miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. Int J Mol Med. 38:183–191. 2016. View Article : Google Scholar : PubMed/NCBI
36	Wei YH, Tang HX, Liao YD, Fu SL, Xu LQ, Chen G, Zhang C, Ju S, Liu ZG, You LK, et al: Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer. J Huazhong Univ Sci Technolog Med Sci. 35:834–841. 2015. View Article : Google Scholar : PubMed/NCBI
37	Min HY, Yun HJ, Lee JS, Lee HJ, Cho J, Jang HJ, Park SH, Liu D, Oh SH, Lee JJ, et al: Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer. 14:1132015. View Article : Google Scholar : PubMed/NCBI
38	Song L, Dai Z, Zhang S, Zhang H, Liu C, Ma X, Liu D, Zan Y and Yin X: MicroRNA-1179 suppresses cell growth and invasion by targeting sperm-associated antigen 5-mediated Akt signaling in human non-small cell lung cancer. Biochem Biophys Res Commun. 504:164–170. 2018. View Article : Google Scholar : PubMed/NCBI
39	Jiang W, Wei K, Pan C, Li H, Cao J, Han X, Tang Y, Zhu S, Yuan W, He Y, et al: MicroRNA-1258 suppresses tumour progression via GRB2/Ras/Erk pathway in non-small-cell lung cancer. Cell Prolif. 51:e125022018. View Article : Google Scholar : PubMed/NCBI
40	Yang JZ, Bian L, Hou JG and Wang HY: MiR-550a-3p promotes non-small cell lung cancer cell proliferation and metastasis through down-regulating TIMP2. Eur Rev Med Pharmacol Sci. 22:4156–4165. 2018.PubMed/NCBI
41	Iqbal MA, Arora S, Prakasam G, Calin GA and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. Aug 17–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
42	Rao C, Miao X, Zhao G, Zhang C, Shen H, Dong C and Yang M: MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Biomed Pharmacother. 114:1086622019. View Article : Google Scholar : PubMed/NCBI
43	Zhang MY, Lin J and Kui YC: MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1. Eur Rev Med Pharmacol Sci. 23:2436–2443. 2019.PubMed/NCBI
44	Li X, Zhu J, Liu Y, Duan C, Chang R and Zhang C: MicroRNA-331-3p inhibits epithelial-mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/β-catenin axis in non-small-cell lung cancer. Cancer Sci. Apr 7–2019.doi: 10.1111/cas.14014 (Epub ahead of print). View Article : Google Scholar
45	Hu Q, Gong JP, Li J, Zhong SL, Chen WX, Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH and Tang JH: Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014. View Article : Google Scholar : PubMed/NCBI
46	Ge J and Chen Z, Wu S, Chen J, Li X, Li J, Yin J and Chen Z: Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion. 80:148–158. 2009. View Article : Google Scholar : PubMed/NCBI
47	Ochnik AM and Baxter RC: Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer. BMC Cancer. 17:8202017. View Article : Google Scholar : PubMed/NCBI
48	Maris C, D'Haene N, Trépant AL, Le Mercier M, Sauvage S, Allard J, Rorive S, Demetter P, Decaestecker C and Salmon I: IGF-IR: A new prognostic biomarker for human glioblastoma. Br J Cancer. 113:729–737. 2015. View Article : Google Scholar : PubMed/NCBI
49	Tracz AF, Szczylik C, Porta C and Czarnecka AM: Insulin-like growth factor-1 signaling in renal cell carcinoma. BMC Cancer. 16:4532016. View Article : Google Scholar : PubMed/NCBI
50	Kim CK, Oh S, Kim SJ, Leem SH, Heo J and Chung SH: Correlation of IGF1R expression with ABCG2 and CD44 expressions in human osteosarcoma. Genes Genomics. 40:381–388. 2018. View Article : Google Scholar : PubMed/NCBI